TuHURA Biosciences (HURA) financial statements
TuHURA Biosciences reported revenue of $0 in fiscal 2025.
Net income was -$30M.
Free cash flow was -$28M.
The diluted share count rose 114770% over the period (dilution).
Income statement
Fiscal years, from TuHURA Biosciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 | 2024 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | — | $0 | $0 |
| Research and development | -$7M | $4M | $4M | $12M | $15M | $9M | $9M | $3M | $13M | $21M |
| Selling, general and admin | -$4M | $5M | $5M | $10M | $8M | $5M | $4M | $6M | $4M | $8M |
| Interest expense | — | — | — | $30,000 | — | — | $18,688 | — | $4M | $625,283 |
| Pre-tax income | — | — | — | — | — | — | $29M | — | -$22M | -$30M |
| Income tax | — | — | — | — | — | — | $0 | — | $3,768 | $1,600 |
| Net income | $11M | -$8M | -$9M | -$38M | -$23M | -$15M | -$29M | -$8M | -$22M | -$30M |
| EPS (diluted) | $271.00 | $158.00 | -$43.50 | -$80.00 | -$25.80 | -$9.27 | -$2.47 | -$0.32 | -$1.21 | -$0.63 |
| Diluted shares | 0M | 0M | 0M | 1M | 1M | 2M | 12M | 26M | 19M | 48M |
Balance sheet
Fiscal years, from TuHURA Biosciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 | 2024 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $6M | $4M | $2M | $11M | $12M | $2M | $4M | $5M | $13M | $4M |
| Total current assets | $7M | $4M | $3M | $12M | $13M | $3M | $4M | $6M | $20M | $5M |
| Property, plant and equipment | — | — | $2,000 | $150,000 | $90,000 | $709,000 | $182,170 | $674,000 | $123,366 | $300,639 |
| Goodwill | — | — | — | — | — | — | — | — | — | $11M |
| Total assets | $7M | $4M | $3M | $14M | $16M | $4M | $4M | $6M | $20M | $27M |
| Total current liabilities | $2M | $2M | $3M | $3M | $4M | $3M | $4M | $2M | $5M | $6M |
| Total liabilities | $2M | $2M | $3M | $3M | $4M | $3M | $6M | $2M | $5M | $6M |
| Shareholders' equity | $5M | $2M | $263,000 | $11M | $12M | $731,000 | -$2M | -$7M | $15M | $21M |
| Net debt | -$6M | -$4M | -$2M | -$11M | -$12M | -$2M | -$4M | -$5M | -$13M | -$4M |
Cash flow
Fiscal years, from TuHURA Biosciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 | 2024 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10M | -$6M | -$8M | -$19M | -$20M | -$12M | -$12M | -$7M | -$15M | -$28M |
| Capital spending | $79,910 | $79,910 | $80,000 | $80,000 | $360,000 | $859,000 | $79,224 | $879,000 | $57,906 | $76,083 |
| Free cash flow | -$10M | -$6M | -$8M | -$19M | -$21M | -$13M | -$12M | -$8M | -$15M | -$28M |
| Stock-based compensation | $495,925 | $426,029 | $495,000 | $5M | $2M | $1M | $478,890 | $607,000 | $2M | $6M |
| Share buybacks (net) | — | — | — | — | — | — | -$24,751 | — | — | — |
| Net borrowing | — | — | — | -$500,000 | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for HURA.
Open HURA in InvestinglyQuestions
What was TuHURA Biosciences's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does TuHURA Biosciences generate?
-$28M in fiscal 2025 (operating cash flow minus capital spending).
From TuHURA Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.